Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT03817398 : Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

<25Age Under 25

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaChronic Myelogenous Leukaemia

Trial Overview Read MoreRead more

This phase II trial is evaluating whether stopping targeted therapy (tyrosine kinase inhibitors) affects treatment-free remission in people with chronic phase myeloid leukaemia.
 

This trial is treating patients with chronic myeloid leukaemia.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You are currently receiving treatment for your cancer.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Cooperative Group

Children's Oncology Group

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

Tyrosine kinase inhibitors (TKIs) are a type of medication that help keep the level of disease low (called molecular remission). However, after being in molecular remission for a specific amount of time, it may not be necessary to take TKIs. This trial is investigating whether stopping TKIs will help patients with chronic myeloid leukaemia in chronic phase continue or re-achieve molecular remission. Participants in this trial will stop taking tyrosine kinase inhibitor (TKI) medication within 10 days of trial enrolment. Participants will then undergo peripheral blood collection to monitor loss of major molecular remission (MMR) every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Participants who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next